The stock of Intra-Cellular Therapies Inc (ITCI) has gone down by -0.54% for the week, with a 45.47% rise in the past month and a 60.78% rise in the past quarter. The volatility ratio for the week is 0.60%, and the volatility levels for the past 30 days are 2.68% for ITCI. The simple moving average for the last 20 days is 30.09% for ITCI stock, with a simple moving average of 63.16% for the last 200 days.
Is It Worth Investing in Intra-Cellular Therapies Inc (NASDAQ: ITCI) Right Now?
ITCI has 36-month beta value of 0.70. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 5 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ITCI is 99.30M, and currently, short sellers hold a 1.99% ratio of that float. The average trading volume of ITCI on January 22, 2025 was 1.77M shares.
ITCI) stock’s latest price update
Intra-Cellular Therapies Inc (NASDAQ: ITCI)’s stock price has plunge by 0.24relation to previous closing price of 126.20. Nevertheless, the company has seen a -0.54% plunge in its stock price over the last five trading sessions. cnbc.com reported 2025-01-21 that Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Piper Sandler repeating the rating for ITCI by listing it as a “Overweight.” The predicted price for ITCI in the upcoming period, according to Piper Sandler is $92 based on the research report published on September 06, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $83. The rating they have provided for ITCI stocks is “Outperform” according to the report published on January 03rd, 2024.
TD Cowen gave a rating of “Outperform” to ITCI, setting the target price at $75 in the report published on December 11th of the previous year.
ITCI Trading at 39.79% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.17% of loss for the given period.
Volatility was left at 2.68%, however, over the last 30 days, the volatility rate increased by 0.60%, as shares surge +45.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.75% upper at present.
During the last 5 trading sessions, ITCI fell by -0.54%, which changed the moving average for the period of 200-days by +87.91% in comparison to the 20-day moving average, which settled at $97.24. In addition, Intra-Cellular Therapies Inc saw 51.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from Mates Sharon, who sale 51,000 shares at the price of $85.80 back on Dec 04 ’24. After this action, Mates Sharon now owns 1,070,329 shares of Intra-Cellular Therapies Inc, valued at $4,375,659 using the latest closing price.
Mates Sharon, the Chairman and CEO of Intra-Cellular Therapies Inc, sale 51,697 shares at $84.08 during a trade that took place back on Dec 05 ’24, which means that Mates Sharon is holding 1,070,329 shares at $4,346,842 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.92 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.14. The total capital return value is set at -0.1. Equity return is now at value -9.90, with -8.46 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -3.51. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -27.97.
Currently, EBITDA for the company is -158.85 million with net debt to EBITDA at 3.68. When we switch over and look at the enterprise to sales, we see a ratio of 21.2. The receivables turnover for the company is 4.21for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.66.
Conclusion
To put it simply, Intra-Cellular Therapies Inc (ITCI) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
